Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE226293 | GEO | 2023/05/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma [scRNA]

Project description:The prevailing view is that myeloid cells in the tumor microenvironment (TME) are immunosuppressive and promote glioblastoma (GBM) progression. However, myeloid cells have the functional plasticity to restrict or support tumor cell growth. TREM2 plays important roles in brain microglial function in neurodegenerative diseases, but the role of TREM2 in the GBM TME has not been examined. We found TREM2 is highly expressed in myeloid subsets, including macrophages and microglia in human and mouse GBM tumors and that high TREM2 expression correlates with poor prognosis in GBM patients. TREM2 loss of function in human macrophages and mouse myeloid cells increased tumoricidal capacity. TREM2 in myeloid cells restricts IFNγ-induced immunoactivation and proinflammatory polarization. In orthotopic mouse GBM models, Trem2-/- mice and mice with acute brain Trem2 reduction demonstrate survival benefit. Trem2 inhibition reprograms myeloid phenotypes and increases PD-1+CD8+ T cells in the TME. Trem2 deficiency enhances the effectiveness of anti-PD-1 treatment and may represent a therapeutic strategy for GBM patients.

2023-05-12 | GSE226292 | GEO

TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma [RNAseq]

2023-05-12 | GSE226172 | GEO

TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma

Project description:TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma

| PRJNA939548 | ENA

TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma [RNAseq]

Project description:TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma [RNAseq]

| PRJNA939127 | ENA

TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma [scRNA]

Project description:TREM2 inhibition triggers anti-tumor cell activity of myeloid cells in glioblastoma [scRNA]

| PRJNA939552 | ENA

TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.

Project description:Checkpoint immunotherapy unleashes T cell control of tumors, but is undermined by immunosuppressive myeloid cells. TREM2 is a myeloid receptor that transmits intracellular signals that sustain microglial responses during Alzheimer's disease. TREM2 is also expressed by tumor-infiltrating macrophages. Here, we found that Trem2-/- mice are more resistant to growth of various cancers than wild-type mice and are more responsive to anti-PD-1 immunotherapy. Furthermore, treatment with anti-TREM2 mAb curbed tumor growth and fostered regression when combined with anti-PD-1. scRNA-seq revealed that both TREM2 deletion and anti-TREM2 are associated with scant MRC1+ and CX3CR1+ macrophages in the tumor infiltrate, paralleled by expansion of myeloid subsets expressing immunostimulatory molecules that promote improved T cell responses. TREM2 was expressed in tumor macrophages in over 200 human cancer cases and inversely correlated with prolonged survival for two types of cancer. Thus, TREM2 might be targeted to modify tumor myeloid infiltrates and augment checkpoint immunotherapy.

| S-EPMC7485282 | biostudies-literature

RNA m6A-Ythdf1 in dendritic cells triggers anti-tumor immunity

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-12-29 | GSE115106 | GEO

Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-06-26 | GSE213789 | GEO

A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-07-14 | E-GEOD-66298 | biostudies-arrayexpress

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:This SuperSeries is composed of the SubSeries listed below.